Can extra support improve life for blood cancer patients?

NCT ID NCT05646576

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special palliative care program (called PEACE) can improve quality of life for people with blood cancers like lymphoma, leukemia, or multiple myeloma who are receiving adoptive cellular therapy (ACT). About 90 participants will be randomly assigned to either standard care or standard care plus the PEACE program, which includes help with symptoms, coping, and treatment decisions. The study lasts up to 2 years and focuses on whether the program is feasible and acceptable to patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Palliative care (PEACE) - a tailored program of symptom management, coping support, and decision-making help

What this could lead to

If it works, this could show that adding palliative care to standard treatment improves quality of life and emotional well-being for blood cancer patients undergoing cellular therapy.

What could go wrong

This is a small, early-stage study focused on feasibility and satisfaction, not on curing the cancer. The intervention may not significantly improve outcomes, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm leukemia lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital Cancer Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••